Cargando…

Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models

Inhibitors of poly(ADP)-ribose polymerase (PARP) exploit defective DNA repair pathways existing in several forms of cancer, such as those with BRCA mutations, and have proven clinical efficacy as chemosensitizers. However, platinum-based chemopotentiation by PARP inhibitors (PARPi), particularly for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stolzenburg, Lindsay R., Ainsworth, Barrett, Riley-Gillis, Bridget, Pakozdi, Tibor, Ammar, Areej, Ellis, Paul A., Wilsbacher, Julie L., Ramathal, Cyril Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729805/ https://www.ncbi.nlm.nih.gov/pubmed/35018214 http://dx.doi.org/10.18632/oncotarget.28162

Ejemplares similares

ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12
por: Li, Lili, et al.
Publicado: (2021)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Recent advances in combinatorial drug screening and synergy scoring
por: Pemovska, Tea, et al.
Publicado: (2018)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Antimicrobial Synergy of Silver-Platinum Nanohybrids With Antibiotics
por: Ranpariya, Bansi, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Discovery of Natural Products With Antifungal Potential Through Combinatorial Synergy
por: Augostine, Catheryn R., et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
por: Gordon, Nicolas, et al.
Publicado: (2023)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2020)

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells
por: Mintz, Rachel L., et al.
Publicado: (2020)

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models
por: Nguyen, Lily L., et al.
Publicado: (2023)

Multifunctional Platinum@BSA–Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation
por: De Luca, Elisa, et al.
Publicado: (2018)

Synergy between chemotherapy and cancer vaccination
por: van der Sluis, Tetje C., et al.
Publicado: (2015)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Functional characterization of a single nucleotide polymorphism associated with Alzheimer’s disease in a hiPSC-based neuron model
por: Stolzenburg, Lindsay R., et al.
Publicado: (2023)

Interpersonal Synergies
por: Riley, Michael A., et al.
Publicado: (2011)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
por: Smith, Hannah L, et al.
Publicado: (2020)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation
por: Zhong, Lan, et al.
Publicado: (2023)

Highly active and durable methanol oxidation electrocatalyst based on the synergy of platinum–nickel hydroxide–graphene
por: Huang, Wenjing, et al.
Publicado: (2015)

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line
por: Baldan, Federica, et al.
Publicado: (2015)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
por: Monk, Bradley J., et al.
Publicado: (2019)

MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery
por: Wooten, David J., et al.
Publicado: (2021)

Dynamical Synergy of Drug Combinations during Cancer Chemotherapy
por: Castorina, Paolo, et al.
Publicado: (2022)

Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
por: Yamamoto, Kimiyo N., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_idiognidqs0auo6vhe73ob5b18